Business Standard

Experts question reliance on monkeypox vax with little data, short supply

The Bavarian Nordic shot has not undergone clinical trials to evaluate the vaccine's ability to prevent monkeypox in humans, though initial studies suggest it will provide some protection

monkeypox
Premium

Photo: Shutterstock

Reuters London
A reliance on vaccines in short supply and questions over their best use are hampering efforts to curb the global spread of monkeypox which has hit dozens of countries for the first time, health officials say.
 
There are just 1.5 million vials of Bavarian Nordic's monkeypox vaccine either administered or currently available in the ten worst-affected countries, which account for nearly 90% of all cases. The vast majority of doses are in the United States. The figures are based on a Reuters tally of government statements, and highlight the extent of the global supply gap for the first time.
 
The

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 23 2022 | 4:00 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com